We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Avacta
AVA6000 set for third dose escalation stageRedx Pharma
All the ingredients for success now in placeRedx Pharma
Jazz Pharmaceuticals $5m milestone triggeredScancell
First Moditope oncology vaccine enters the clinicRedx Pharma
£34.3m raise extends runway through key data pointsArecor Therapeutics
AT278 hits the sweet spotANGLE
Parsortix FDA clearance marks a key transition pointFutura Medical
Major MED3000 deal for Europe with Cooper HealthMaxCyte
Robust Cell Therapy performance lifts FY22 guidanceANGLE
FY21 results: prepared for commercial success